- Champignon Brands (CSE:SHRM) has announced the appointment of Dr Roger McIntyre as Chief Executive Officer
- He replaces Gareth Birdsall, who will retain his position as a director
- According to expertscape.com, Roger is the world’s number one researcher in the field of depression
- Roger is a Professor of Psychiatry and Pharmacology at the University of Toronto, and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto
- Champignon Brands (SHRM) is up 2.06 per cent and trading for C$0.99 per share, with a $157.74 million market cap
Champignon Brands (CSE:SHRM) has announced the appointment of Dr Roger McIntyre as Chief Executive Officer.
He will replace the company’s current CEO, Gareth Birdsall, who will retain his position as a director.
Roger is a Professor of Psychiatry and Pharmacology at the University of Toronto, and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto.
He is also Director and Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) in Chicago.
Among some of his most significant achievements is the establishment of the Canadian Rapid Treatment Centre of Excellence (CRTCE). The Centre provides rapid-onset treatments for people with mood disorders.
Champignon Brands currently holds a 75 per cent stake in the CRTCE, following its acquisition of AltMed Capital in April. The Centre holds a license to administer ketamine for treating depression, bipolar disorder, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD).
Roger has published more than 600 articles on the topic of mood disorders, along with several books. As such, expertscape.com ranked him as the world’s number one researcher in the field of depression.
Clarivate Analytics also ranked him as one of the World’s Most Influential Scientific Minds each year from 2014 to 2019.
Roger said that his overarching aim is to establish Champignon as the “apotheosis of integrated ketamine treatment delivery,” and to commercialise the company’s portfolio of psychedelic-based treatments.
“The clinical infrastructure, complementary asset base and human capital that Champignon has acquired leaves me very confident we will provide life changing treatments for persons with depression, all the while contemporaneously rewarding our investor base.
“The Canadian Rapid Treatment Centre of Excellence, that I envisaged and successfully implemented, is the world’s first integrated clinical and R&D centre in ketamine and psychedelic-based treatments, and is identified as the most influential scientific centre for depression research,” he added.
2020 has been a significant year for the company. Since it listed on the Canadian Securities Exchange (CSE) on March 2, its shares have grown 350 per cent.
Champignon Brands (SHRM) is up 2.06 per cent and trading for C$0.99 per share at 3:41pm EDT.
